Rev. OFIL 2017, 27;2:181-186
Fecha de recepción: 18/05/2016 – Fecha de aceptación: 20/06/2016
Martiarena Ayestarán A, Martínez Martínez C, Mínguez Cabeza AC
Farmacéutico Especialista en Farmacia Hospitalaria. Servicio de Farmacia. Hospital Universitario Araba (Sede Txagorritxu). Vitoria-Gasteiz (España)
Amaia Martiarena Ayestarán
C/Andrearriaga nº 1A 1ºB
20305 Irún (Guipúzcoa)
Correo electrónico: firstname.lastname@example.org
Objective: To calculate, according to clinical practice, the annual median cost per episode of treatment and the percentage of dispensing median dose of tocilizumab, etanercept, adalimumab or infliximab in Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS) or Psoriatic Arthritis (PsA). In addition, compare those results with the theoretical cost and recommended doses.
Method: Observational retrospective study. From January 2009 to December 2013 all adults with RA, AS or PsA treated with these therapies for at least 1 year were included. They were attended at Rheumatology and Pharmacy services.
Results: 251 episodes of treatment were included: 106 of adalimumab, 89 of etanercept, 38 of infliximab and 18 of tocilizumab. Adalimumab was the most usually dispensed drug (42.2%). There were described differences in real cost between two subcutaneous therapies: etanercept was 4.0% cheaper than adalimumab in RA (p=0.012), 12.2% cheaper in EA (p=0.002) and 18.2% more economical in PsA (p=0.001). The real annual median cost was lower than theoretical annual cost per all therapies except for infliximab. Only in RA, the real annual median cost of infliximab was higher than the theoretical cost (p=0.140). In RA, the percentage of dispensed median real dose of tocilizumab (86.7%), etanercept (93.1%) and adalimumab (89.3%) were lower than recommended doses, except for infliximab (114.2%).
Conclusions: Real dosage of etanercept, adalimumab or tocilizumab was lower than recommended dosage.
Key Words: Drug cost, tocilizumab, etanercept, adalimumab, infliximab, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis.